4D Molecular Therapeutics Inc
4dmoleculartherapeutics.comWhat Do They Do?
Develops genetic medicines for people with retinal diseases and lung diseases, including wet AMD, diabetic macular edema and cystic fibrosis.
10-K for FY2025, filed Mar 18, 2026We are a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with the potential to transform…View ↗
Our lead product candidate 4D-150 utilizes our proprietary R100 vector and a transgene encoding anti-VEGF biologics (inhibitors of vascular…View ↗
Our other pipeline programs include 4D-710, which we believe is the first known genetic medicine to demonstrate successful delivery and…View ↗
We have developed a pipeline of product candidates in two therapeutic areas, retina and pulmonology, focusing on disease areas of high…View ↗
How Do They Make Money?
It earns upfront license fees, research funding and expense reimbursements, plus milestone payments tied to development or regulatory events and royalties on product sales. License fees count when a license begins, while research and development work earns revenue as it progresses; royalties are tied to product sales.
10-K for FY2025, filed Mar 18, 2026Our revenue to date has been generated through payments from our collaboration and license agreements, primarily from upfront and milestone…View ↗
The Company’s revenue is primarily derived through its license, research, development and commercialization agreements. The terms of these…View ↗
Payments to the Company under these arrangements typically include one or more of the following: nonrefundable upfront and license fees…View ↗
The Company recognizes as revenue sales-based royalties and milestone payments at the later of (i) when the related sales occur, or (ii)…View ↗
The Company recognizes revenue when, or as, the performance obligation is satisfied. Performance obligations recognized at a point in time…View ↗
$85.2M
-
10-K for FY2025, filed Mar 18, 2026
$85.2M ↗
Who Are Their Customers?
Pharmaceutical partners license its technology and collaborate on development; research foundations provide funding for development programs.
10-K for FY2025, filed Mar 18, 2026The Company’s revenue is primarily derived through its license, research, development and commercialization agreements. The terms of these…View ↗
In October 2025, we entered into a Collaboration and License Agreement with Otsuka Pharmaceutical Co., Ltd. (the “Otsuka Collaboration and…View ↗
Our other pipeline programs include 4D-710, which we believe is the first known genetic medicine to demonstrate successful delivery and…View ↗
Do Revenues Turn Into Profits?
No. It lost $140.1M in FY2025.
10-K for FY2025, filed Mar 18, 2026
−$159.5MView ↗
10-K for FY2025, filed Mar 18, 2026
−$140.1MView ↗
10-K for FY2025, filed Mar 18, 2026
−$109.6MView ↗
How Are They Changing?
Growing. Revenue grew 4.7x in 4 years, from $18M in FY2021 to $85.2M in FY2025, about 47% a year.
Narrower pipeline focus
The older report described candidates across eye, lung and heart diseases; the latest centers development on retinal and lung programs, while other candidates are pursued mainly with external funding and strategic partners.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 18, 2026We are a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment…View ↗
Who Do They Compete With?
Competes with AbbVie, REGENXBIO, Adverum Biotechnologies, EyePoint, Ocular Therapeutix, Kodiak Sciences, Merck &, Regeneron Pharmaceuticals, Roche, Apellis Pharmaceuticals, Astellas Pharma, Annexon Biosciences, Belite Bio, Johnson & Johnson, Alnylam Pharmaceuticals, Sanofi, Stealth BioTherapeutics, Vertex Pharmaceuticals, Sionna Therapeutics, and Krystal Biotech
10-K for FY2025, filed Mar 18, 2026We consider our most direct competitors in late-stage development with respect to 4D-150 for the treatment of retinal vascular diseases…View ↗
Loading...
